IPHA 财务： Innate Pharma SA AI 分析

Q: Innate Pharma SA 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Innate Pharma SA 的总资产为 $111，净损失为 $-49

Q: IPHA 的关键财务比率是什么？

Innate Pharma SA 的流动比率是 1.08，净利 margin 为 -408.33，每股销售为 $0.14。

Q: Innate Pharma SA 的收入按细分市场或地理位置如何划分？

Innate Pharma SA 最大收入来源是 Research and Development of Pharmaceutical Products，在最近的收益报告中收入为 20,121,000。就地区而言， France 是 Innate Pharma SA 的主要市场，收入为 20,121,000。

Q: Innate Pharma SA 是否盈利？

不，根据最新的财务报表，Innate Pharma SA 的净损失为 $-49

Q: Innate Pharma SA 有负债吗？

是的，Innate Pharma SA 的负债为 102

Q: Innate Pharma SA 的流通股有多少？

Innate Pharma SA 的总流通股为 83.81

主页

股票

IPHA

IPHA 财务

Innate Pharma SA

$1.74

-0.96%

$-0.01

收盘价：Jan 16, 16:00:00 GMT-5

$1.74

盘前：Jan 20, 07:30:47 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$1.76

开盘价

$1.8

当日区间

$1.7 - $1.8

52周范围

$1.62 - $2.63

交易量

19.8K

平均成交量

200.4K

每股收益（TTM）

-0.64

股息收益率

市值

$160.6M

什么是 IPHA？

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.

功能特性

交易策略

资源

市场

收入

资产负债表

现金流量

年度

季度性

IPHA 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	6	12	51	49	12	56
营收同比增长 (YoY)	-75%	-76%	4%	308%	-79%	-18%
营收成本	3	3	2	3	3	3
毛利润	2	9	49	45	9	52
销售、一般及管理费用	18	18	16	20	23	17
研发	40	48	49	45	41	37
营业费用	53	61	61	62	56	51
其他非经营性收入 (费用)	0	1	1	-1	1	0
税前利润	-46	-49	-7	-57	-45	0
所得税费用	0	0	0	0	0	0
净利润	-46	-49	-7	-58	-52	-63
净利润增长	35%	600%	-88%	12%	-17%	215%
稀释后流通股数	86.93	81.05	80.45	79.63	79.54	78.93
股份同比变动 (YoY)	8%	1%	1%	0%	1%	18%
每股收益 (摊薄)	-0.54	-0.61	-0.09	-0.72	-0.66	-0.81
每股收益增长率	30%	549%	-87%	10%	-19%	161%
自由现金流	-41	-7	-34	-20	-59	-63
每股自由现金流	--	--	--	--	--	--
毛利率	33.33%	75%	96.07%	91.83%	75%	92.85%
营业利润率	-833.33%	-425%	-23.52%	-32.65%	-391.66%	1.78%
净利率	-766.66%	-408.33%	-13.72%	-118.36%	-433.33%	-112.5%
自由现金流利润率	-683.33%	-58.33%	-66.66%	-40.81%	-491.66%	-112.5%
EBITDA	-49	-50	-7	29	-43	57
EBITDA 利润率	-816.66%	-416.66%	-13.72%	59.18%	-358.33%	101.78%
EBITDA 中的折旧与摊销	1	1	5	45	4	56
EBIT	-50	-51	-12	-16	-47	1
EBIT 利润率	-833.33%	-425%	-23.52%	-32.65%	-391.66%	1.78%
有效税率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Innate Pharma SA 的关键财务报表是什么？



IPHA 的关键财务比率是什么？



Innate Pharma SA 的收入按细分市场或地理位置如何划分？



Innate Pharma SA 是否盈利？



Innate Pharma SA 有负债吗？



Innate Pharma SA 的流通股有多少？



Innate Pharma SA（IPHA）价格

IPHA 股价走势图